Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib study of NZV930 alone and with PDR001 and/or NIR178 in advanced malignancies (Japan)
jRCT2080224562Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Vaccines & Immunotherapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of NZV930 in advanced nonhematological malignancy (4 arms), sponsored by Novartis. Primary endpoints: Recommended dose determination and Safety and tolerability. Started Feb 2019; status: completed.
02
Drugs
NZV930
03
Conditions
advanced nonhematological malignancy
Beyond the preview
Go deeper on jRCT2080224562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224562.